Building on this approach, VSV engineered to express IL-2 or IL-2 mimics has been shown to act as a potent adjuvant for cancer vaccination, locally stimulating T and NK cells while avoiding the systemic toxicity of recombinant cytokines (Clinical Trial NCT02285816) [110]. The gene discussed is IL2; the disease is cancer.